{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:00:47Z","timestamp":1783443647853,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40271-024-00699-2","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:02:04Z","timestamp":1715774524000},"page":"685-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patients\u2019 Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment"],"prefix":"10.1007","volume":"17","author":[{"given":"Alexander","family":"Keenan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-8985","authenticated-orcid":false,"given":"Chiara","family":"Whichello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela S.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Quaife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Perrin","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"issue":"10","key":"699_CR1","first-page":"1935","volume":"70","author":"PA Calabresi","year":"2004","unstructured":"Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Phys. 2004;70(10):1935\u201344.","journal-title":"Am Fam Phys"},{"issue":"3","key":"699_CR2","first-page":"175","volume":"37","author":"MM Goldenberg","year":"2012","unstructured":"Goldenberg MM. Multiple sclerosis review. P T. 2012;37(3):175\u201384.","journal-title":"P T"},{"issue":"11","key":"699_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","volume":"83","author":"P Browne","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022\u20134.","journal-title":"Neurology"},{"key":"699_CR4","unstructured":"GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1083-97."},{"issue":"11 Suppl 5","key":"699_CR5","first-page":"S12","volume":"63","author":"H Crayton","year":"2004","unstructured":"Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S12\u20138.","journal-title":"Neurology"},{"issue":"4","key":"699_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clinthera.2006.04.005","volume":"28","author":"HJ Crayton","year":"2006","unstructured":"Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther. 2006;28(4):445\u201360.","journal-title":"Clin Ther"},{"issue":"5","key":"699_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401.","journal-title":"N Engl J Med"},{"issue":"2","key":"699_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","volume":"81","author":"J Chun","year":"2021","unstructured":"Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs. 2021;81(2):207\u201331.","journal-title":"Drugs"},{"key":"699_CR9","unstructured":"Novartis Pharmaceuticals Corporation. GILENYA (fingolimod) capsules [package insert]. US FDA; 2012."},{"key":"699_CR10","unstructured":"Novartis Pharmaceuticals Corporation. MAYZENT\u00ae (siponimod) tablets, for oral use [package insert]. US FDA; 2019."},{"key":"699_CR11","unstructured":"Celgene Corporation. ZEPOSIA\u00ae (ozanimod) capsules, for oral use [package insert]. US FDA; 2020."},{"key":"699_CR12","unstructured":"Janssen Pharmaceuticals. PONVORY\u2122 (ponesimod) tablets, for oral use [package insert]. US FDA; 2021."},{"key":"699_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103908","volume":"64","author":"B Hennessy","year":"2022","unstructured":"Hennessy B, Zierhut ML, Kracker H, Keenan A, Sidorenko T. Comparative efficacy of relapsing multiple sclerosis therapies: model-based meta-analyses for confirmed disability accumulation and annualized relapse rate. Mult Scler Relat Disord. 2022;64: 103908.","journal-title":"Mult. Scler. Relat. Disord."},{"key":"699_CR14","doi-asserted-by":"crossref","unstructured":"Tong J, Zou Q, Chen Y, Liao X, Chen R, Zhang D, Li Q. Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. Neurol. Sci. 2021;42.","DOI":"10.1007\/s10072-021-05049-w"},{"key":"699_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-1495-4","volume-title":"Multiple criteria decision analysis: an integrated approach","author":"V Belton","year":"2002","unstructured":"Belton V, Stewart T. Multiple criteria decision analysis: an integrated approach. New York: Springer; 2002."},{"issue":"9","key":"699_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883\u2013902.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"699_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201\u201326.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"699_CR18","doi-asserted-by":"publisher","first-page":"i55","DOI":"10.1136\/qhc.0100055","volume":"10","author":"M Ryan","year":"2001","unstructured":"Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete choice experiments to elicit preferences. Qual Health Care. 2001;10(Suppl 1):i55\u201360.","journal-title":"Qual Health Care"},{"issue":"8","key":"699_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14737175.2020.1806062","volume":"20","author":"SB Patten","year":"2020","unstructured":"Patten SB. Current perspectives on co-morbid depression and multiple sclerosis. Expert Rev Neurother. 2020;20(8):867\u201374.","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"699_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/09540261.2017.1322555","volume":"29","author":"SB Patten","year":"2017","unstructured":"Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis. Int Rev Psychiatry. 2017;29(5):463\u201372.","journal-title":"Int Rev Psychiatry"},{"issue":"4","key":"699_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/jnnp.2004.054635","volume":"76","author":"RJ Siegert","year":"2005","unstructured":"Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76(4):469.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"699_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40271-024-00672-z","volume":"17","author":"NB Campoamor","year":"2024","unstructured":"Campoamor NB, Guerrini CJ, Brooks WB, Bridges JFP, Crossnohere NL. Pretesting discrete-choice experiments: a guide for researchers. The Patient Patient-Center Outcomes Res. 2024;17(2):109\u201320.","journal-title":"The Patient Patient-Center Outcomes Res."},{"issue":"1","key":"699_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3\u201313.","journal-title":"Value Health."},{"issue":"5","key":"699_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373\u201384.","journal-title":"Patient"},{"key":"699_CR25","doi-asserted-by":"crossref","unstructured":"Rose J, Bliemer M. Sample size requirements for stated choice experiments. Transportation. 2013;40.","DOI":"10.1007\/s11116-013-9451-z"},{"key":"699_CR26","unstructured":"ChoiceMetrics. Ngene 1.2 User Manual and Reference Guide 2019."},{"issue":"5","key":"699_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/01441640902827623","volume":"29","author":"JM Rose","year":"2009","unstructured":"Rose JM, Bliemer MC. Constructing efficient stated choice experimental designs. Transp Rev. 2009;29(5):587\u2013617.","journal-title":"Transp Rev"},{"issue":"2","key":"699_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, Yang JC, Reed SD. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2019;22(2):157\u201360.","journal-title":"Value Health."},{"issue":"8","key":"699_CR29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/hec.1104","volume":"15","author":"E Lancsar","year":"2006","unstructured":"Lancsar E, Louviere J. Deleting \u201cirrational\u201d responses from discrete choice experiments: a case of investigating or imposing preferences? Health Econ. 2006;15(8):797\u2013811.","journal-title":"Health Econ"},{"issue":"4","key":"699_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health."},{"key":"699_CR31","unstructured":"McFadden D. Econometric models of probabilistic choice. In: Manski C, McFadden D, editors. Structural analysis of discrete data with econometric applications. Cambridge: MIT Press; 1981."},{"issue":"7","key":"699_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40273-017-0506-4","volume":"35","author":"E Lancsar","year":"2017","unstructured":"Lancsar E, Fiebig DG, Hole AR. Discrete choice experiments: a guide to model specification, estimation and software. Pharmacoeconomics. 2017;35(7):697\u2013716.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"699_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/0272989X19897944","volume":"40","author":"MF Jonker","year":"2020","unstructured":"Jonker MF, Donkers B, Goossens LMA, Hoefman RJ, Jabbarian LJ, de Bekker-Grob EW, et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Making. 2020;40(2):198\u2013211.","journal-title":"Med Decis Making"},{"issue":"4","key":"699_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40271-017-0296-y","volume":"11","author":"EJD Webb","year":"2018","unstructured":"Webb EJD, Meads D, Eskyte I, King N, Dracup N, Chataway J, et al. A systematic review of discrete-choice experiments and conjoint analysis studies in people with multiple sclerosis. Patient. 2018;11(4):391\u2013402.","journal-title":"Patient"},{"key":"699_CR35","doi-asserted-by":"crossref","unstructured":"Alonso R, Carnero Contentti E, Gra\u00f1a M, Linares R, Lopez P, Mainella C, et al. Shared decision making in the treatment of multiple sclerosis: a consensus based on Delphi methodology. Multiple Scler Relat Disord. 2023;70(104465).","DOI":"10.1016\/j.msard.2022.104465"},{"key":"699_CR36","doi-asserted-by":"publisher","first-page":"1063904","DOI":"10.3389\/fneur.2022.1063904","volume":"13","author":"DT Ubbink","year":"2022","unstructured":"Ubbink DT, Damman OC, de Jong BA. Shared decision-making in patients with multiple sclerosis. Front Neurol. 2022;13:1063904.","journal-title":"Front Neurol"},{"issue":"4","key":"699_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health."},{"key":"699_CR38","unstructured":"International Society for Pharmacoeconomics Outcomes Research (ISPOR). ISPOR Good Practices for Outcomes Research Index 2018. https:\/\/www.ispor.org\/heor-resources\/good-practices-for-outcomes-research."},{"issue":"9","key":"699_CR39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jval.2019.04.1924","volume":"22","author":"EW de Bekker-Grob","year":"2019","unstructured":"de Bekker-Grob EW, Swait JD, Kassahun HT, Bliemer MCJ, Jonker MF, Veldwijk J, et al. Are healthcare choices predictable? The impact of discrete choice experiment designs and models. Value Health. 2019;22(9):1050\u201362.","journal-title":"Value Health."},{"issue":"8","key":"699_CR40","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s10198-018-0954-6","volume":"19","author":"M Quaife","year":"2018","unstructured":"Quaife M, Terris-Prestholt F, Di Tanna GL, Vickerman P. How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity. Eur J Health Econ. 2018;19(8):1053\u201366.","journal-title":"Eur J Health Econ"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00699-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-024-00699-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00699-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T02:09:41Z","timestamp":1728439781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-024-00699-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s40271-024-00699-2","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"18 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Janssen. The sponsor was involved in the study design but had no role in data collection, data analysis, data interpretation, or writing of the statistical report. All authors had full access to the study data and had final responsibility for the decision to submit this article for publication. CW, GSF, VT, AD, and MQ are employees of Evidera, part of the clinical research group within Thermo Fisher Scientific, which received funding from Janssen to conduct this study. AK, HHL, and DMK are employees of Janssen and may own Johnson & Johnson stocks. APR reports having received consulting fees from Janssen. Medical writing was provided by Jacqueline Janowich Wasserott (Evidera) and was funded by Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AK: Conceptualization, methodology, software, writing\u2014original draft, writing\u2014review and editing, supervision. CW: Conceptualization, methodology, validation, formal analysis, investigation, data curation, writing\u2014original draft, writing\u2014review and editing, visualization, supervision, project administration. HHL: Conceptualization, methodology, writing\u2014original draft, writing\u2014review and editing, supervision. DMK: Conceptualization, methodology, writing\u2014review and editing, supervision. GSF: Conceptualization, methodology, validation, investigation, data curation, writing\u2014original draft, writing\u2014review and editing, project administration. VT: Methodology, validation, investigation, data curation, writing\u2014original draft, writing\u2014review and editing. AD: Methodology, validation, formal analysis, investigation, data curation, writing\u2014review and editing, visualization. MQ: Conceptualization, methodology, validation, formal analysis, investigation, data curation, writing\u2014original draft, writing\u2014review and editing, supervision. APR: Conceptualization, writing\u2014review and editing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Chiara Whichello, Gabriela S. Fernandez, Vicky Turner, Anup Das, and Matthew Quaife are employees of Evidera, which received funding from Janssen to conduct this study. Alexander Keenan, Hoa H. Le, and David M. Kern are employees of Janssen and may own Johnson & Johnson stocks. Amy Perrin Ross reports having received consulting fees from EMD Serono, BMS, Novartis, Janssen, Genzyme, Horizon, Alexion, TG Therapeutics, Roche, and Merke, as well as payments or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from EMD Serono, BMS, Novartis, Genzyme, Horizon, Alexion, and TG Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The informed consent obtained from participants does not allow for individual data to be made publicly available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}